| Dr John J Petrus, MD | |
|
224 W Exchange St, Suite 160, Akron, OH 44302-1704 | |
| (330) 344-6767 | |
| (330) 867-1195 |
| Full Name | Dr John J Petrus |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 40 Years |
| Location | 224 W Exchange St, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730151846 | NPI | - | NPPES |
| 0303081 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 35-05-2725 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southwest General Health Center | Middleburg heights, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest General Medical Group Inc | 8527964550 | 163 |
| The Petrus Group, Inc. | 0648291567 | 2 |
News Archive
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV's surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
HighRoads, the company providing employers – for the first time – complete control over their health care costs and compliance, today announced findings from the industry's first medical travel request for information (RFI) for Fortune 500 employers to compare health care procedural ethics, quality and costs around the world.
New research presented today at the American Heart Association Scientific Sessions suggests neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance.
› Verified 7 days ago
| Entity Name | Southwest General Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134239676 PECOS PAC ID: 8527964550 Enrollment ID: O20031210000789 |
News Archive
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV's surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
HighRoads, the company providing employers – for the first time – complete control over their health care costs and compliance, today announced findings from the industry's first medical travel request for information (RFI) for Fortune 500 employers to compare health care procedural ethics, quality and costs around the world.
New research presented today at the American Heart Association Scientific Sessions suggests neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance.
› Verified 7 days ago
| Entity Name | The Petrus Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134230915 PECOS PAC ID: 0648291567 Enrollment ID: O20051207000642 |
News Archive
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV's surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
HighRoads, the company providing employers – for the first time – complete control over their health care costs and compliance, today announced findings from the industry's first medical travel request for information (RFI) for Fortune 500 employers to compare health care procedural ethics, quality and costs around the world.
New research presented today at the American Heart Association Scientific Sessions suggests neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John J Petrus, MD 224 W Exchange St, Suite 160, Akron, OH 44302-1704 Ph: (330) 344-6767 | Dr John J Petrus, MD 224 W Exchange St, Suite 160, Akron, OH 44302-1704 Ph: (330) 344-6767 |
News Archive
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV's surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
HighRoads, the company providing employers – for the first time – complete control over their health care costs and compliance, today announced findings from the industry's first medical travel request for information (RFI) for Fortune 500 employers to compare health care procedural ethics, quality and costs around the world.
New research presented today at the American Heart Association Scientific Sessions suggests neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance.
› Verified 7 days ago
Dr. Michael A Pelini, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |